Drug labeling by the US Food and Drug Administration is intended to help clinicians avoid medication use in specific high-risk patient groups. However, there are few studies on the extent of contraindicated medication use in clinical practice. [2] [3] [4] [5] Percutaneous coronary intervention (PCI) is a clinical setting in which contraindicated medication use may occur. These procedures are often performed urgently or emergently, when patient data may not be readily available for review by the provider ordering medications. For example, a previous study highlighted contraindicated use of anticoagulant medications in 22.3% of dialysis patients undergoing PCI.
which records medication data from all PCIs performed in the VA healthcare system, we sought to describe the use of contraindicated medications in the setting of PCI. We evaluated both medications given during the PCI procedure and medications received on discharge from the hospital. Then, we determined the risk-adjusted association between contraindicated use of the procedural medications and outcomes of periprocedural bleeding and all-cause mortality. These findings may guide future opportunities to further reduce patient harm related to contraindicated medication use.
Methods Study Population, Setting, and Data Source
Using VA CART Program data, we studied all Veterans undergoing PCI in the VA between October 1, 2007 and September 30, 2013 (n=64 294). The VA CART Program is a national clinical quality program for VA cardiac catheterization laboratories. The CART Program uses a software application embedded in the VA electronic medical record (EMR) for medical record documentation of cardiac catheterization laboratory procedures. In the process of clinical documentation of catheterization laboratory procedures, the software application collects key patient and procedural data on all coronary procedures conducted in VA nationwide. These data are then linked to the VA EMR, allowing for linkage to longitudinal mortality, hospitalization, outpatient visit, pharmacy, and laboratory data. In addition, the CART data are linked to fee-based data for those hospitalizations at non-VA centers, where the VA pays for the Veterans' care.
Data elements in the CART application are standardized and based on the National Cardiovascular Data Registry (NCDR). 6 A dedicated staff provides continuous monitoring, maintenance, and updating of the application. Data quality checks are periodically conducted for completeness and accuracy. Additional detail on CART and the validity, completeness, and timeliness of CART data have been previously described. [7] [8] [9] [10] The analysis was approved by the Colorado Multiple Institutional Review Board.
Antiplatelet Medication Contraindications
We evaluated the following commonly used antiplatelet medications used in the setting of PCI: prasugrel, ticagrelor, abciximab, eptifibatide, or tirofiban. Medication contraindications were defined in accordance (Table 1) . Although it is the most commonly used P2Y12 inhibitor with known contraindications, clopidogrel was not included in this analysis because we were unable to assess for its 2 package insert contraindications (active pathological bleeding and hypersensitivity to clopidogrel). The presence of absolute medication contraindications for individual patients was determined by assessing the most recent blood pressure within 7 days before PCI to identify patients with severe hypertension (70% were captured at the time of PCI and 87% were captured within 1 day of PCI), the most recent laboratory values within 30 days before PCI to identify patients with thrombocytopenia, and any International Classification of Diseases Ninth Revision code within the EMR that matched with a known Food and Drug Administration package insert contraindicated comorbid condition (Table I in 
Antiplatelet Medication Use
Receipt of periprocedural antiplatelet medication was determined from VA CART data and supplemented with VA pharmacy data. Periprocedural medications were defined as any medication given on the day of PCI (either before or during the procedure) as determined from provider documentation in the clinical record. Discharge medications were determined from the VA pharmacy data and defined as any medication prescribed within 90 days of PCI.
Outcomes
All-cause mortality was determined through the VA vital status file, which compiles data from the BIRLS Death file, VA Medicare Vital Status File, and the Social Security Administration Death Master File, and censored at 30 days. 11 Periprocedural major bleeding events
WHAT IS KNOWN
• Medication errors contribute to >100 000 deaths and >$170 billion in annual spending.
• Among dialysis patients undergoing percutaneous coronary intervention, 22% received a contraindicated periprocedural antithrombotic medication, leading to an increased risk of major bleeding.
WHAT THE STUDY ADDS
• Nearly 20% of patients undergoing percutaneous coronary intervention had a known contraindication to 1 of 5 antiplatelet medications.
• Overall, rates of contraindicated antiplatelet medication use among percutaneous coronary intervention patients was low (1.1%).
• However, patients who received contraindicated abciximab experienced a 2-fold increased risk of major bleeding. were defined as occurring within 3 days of PCI, along with one of the following: (1) occurring in a critical organ as coded during the index hospitalization, (2) a hemoglobin drop of 2+ g/dL, or (3) any required blood transfusion (Table II in the Data Supplement) . 12 Patient outcomes were only assessed in relation to periprocedural medication use because the number of patients receiving contraindicated medications at discharge was insufficient to support risk-adjusted analyses.
Covariates
We assessed patient demographics, clinical comorbid conditions, previous cardiac procedures, and the acuity of clinical presentations from VA CART and administrative data using standard definitions. Previous major bleeding was defined based on International Classification of Diseases Ninth Revision codes within the EMR before the procedure (Table II in the Data Supplement). The risk score for bleeding was based on the NCDR bleeding risk model. 13 Race and ethnicity were missing in ≈5% of the cohort. Missing values for these covariates were imputed using regression methods.
Statistical Analysis
Among all patients with PCI, we first identified patients undergoing PCI with at least 1 contraindication to commonly used antiplatelet medications. Among patients with a medication contraindication, we compared the demographics and clinical characteristics of patients who received a contraindicated medication with those patients who did NOT receive a contraindicated medication. Comparisons were conducted using χ 2 tests for categorical variables and Mann-Whitney U nonparametric tests for continuous variables. We also estimated the cumulative incidence of outcomes at the end of the follow-up times (3 days for periprocedural bleeding and 30 days for mortality) among patients with at least 1 drug contraindication, stratified by receipt of the medication and compared using Gray test, accounting for death as a competing risk for the bleeding.
To adjust for differences in baseline bleeding and mortality risk between patients who did and did not receive contraindicated medications, adjusted outcomes were assessed using 3 subcohorts of patients with the same contraindication for a specific antiplatelet medication. We chose the 3 subcohorts with adequate sample size for this analysis that were identified from our descriptive analyses: (1) patients with a contraindication for abciximab because of a stroke in the previous 2 years (n=2614), (2) patients with a contraindication for abciximab because of thrombocytopenia (n=3154), and (3) male patients with a contraindication for eptifibatide because of dialysis (n=1704). We excluded females (n=21) from the subcohort of patients with a contraindication to eptifibatide because no women in this subcohort were given the contraindicated medication.
Within each subcohort, we estimated the propensity to receive the contraindicated medication using a binary logistic regression model with covariates for diabetes mellitus, hyperlipidemia, hypertension, history of tobacco use, heart failure, cerebrovascular disease, peripheral artery disease, obesity, chronic obstructive pulmonary disease, age, race, Hispanic ethnicity, acute coronary syndrome, NCDR PCI bleeding risk score, previous myocardial infarction, previous PCI, previous coronary artery bypass surgery, and previous major bleeding. The models for abciximab also included sex and chronic kidney disease. Because dialysis is a known contraindication for eptifibatide use, all patients would also have chronic kidney disease and, therefore, it was not included as a comorbidity in the propensity model. From the propensity score, we calculated the inverse probability weight and truncated the value at the highest 97.5th percentile and the lowest 2.5th percentile. [14] [15] [16] The balance in the propensity-weighted cohort was evaluated using standardized differences for all covariates, and sensitivity analyses with various truncation thresholds are provided to assess the potential bias of truncation ( Figure I and Table  III in the Data Supplement) . 16 An absolute difference of <10% in all variables is commonly considered adequate balance. 17 All covariates showed adequate balance based on this measure, except for sex in the previous stroke cohort, which we included in the outcome model.
Within these subcohorts, the association between receipt of a contraindicated medication and patient outcomes was first compared with cumulative incidence curves, both unweighted and weighted by the inverse probability weight to adjust for risk, and accounting for death as a competing risk for the bleeding outcome.
For the outcome models, we used Cox proportional hazards models with robust estimators of the covariance matrix to account for clustering by site and weighted by the inverse probability weight, including the main effect for whether the patient received the contraindicated medication as the only predictor (with the exception noted above for the previous stroke cohort). Further details on the specifications of this outcome model are provided in the Appendix I in the Data Supplement.
Sensitivity Analyses
Use of a glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibitor medication may occur as a bailout strategy for patients presenting with ST-segmentelevation myocardial infarction (STEMI). In this setting, there may be no good alternatives to the use of a contraindicated Gp IIb/IIIa inhibitor. To determine the extent of contraindicated use that may have resulted from bailout use of these agents, we repeated our analyses after exclusion of patients presenting with STEMI.
Intravenous or subcutaneous anticoagulants, such as unfractionated heparin, low-molecular-weight heparin, and fondaparinux, are associated with periprocedural bleeding risk. For that reason, we included use of any periprocedural anticoagulant as a covariate in the cox proportional hazards models in a second sensitivity analysis.
Results
Of the 64 294 patients who underwent PCI, 11 315 (17.6%) had a condition that would make at least 1 antiplatelet agent's use contraindicated. Among patients with a contraindication to at least 1 antiplatelet medication, 737 (6.5%; 1.1% of total PCI population) patients received a contraindicated medication in the periprocedural setting or at hospital discharge (Table 2) . Values represent the number of patients receiving a medication out of the total number of patients with a contraindicated state. *Previous stroke defined as within 2 years for abciximab, within 30 days for eptifibatide and tirofiban, and any previous stroke for prasugrel.
Abciximab and eptifibatide were the most commonly used medications in the periprocedural setting. Of the 5736 patients with ≥1 contraindication to abciximab, it was used in 17 patients with severe hypertension, 147 with thrombocytopenia, and 115 with a previous stroke. Of the 2518 patients with ≥1 contraindications to eptifibatide, it was used in 49 patients with severe hypertension, 68 with a previous intracranial hemorrhage, 70 with a previous stroke, and 162 who were on dialysis. Between 2007 and 2013, a decline in the overall use of abciximab (6.9%-3.0% of all PCI) and eptifibatide (22.9%-12.0%) was seen (P<0.001 for both). Among patients receiving a contraindicated medication, 682 (92.5%) patients received a contraindicated medication during the PCI procedure and 88 (11.9%) patients received a contraindicated medication at hospital discharge. Some patients received contraindicated medications in both settings. Contraindicated discharge medication use included prasugrel in 85 of 6696 (1.3%) patients with a previous stroke and ticagrelor in 2 of 873 (0.2%) of patients with cirrhosis and 1 of 326 (0.3%) of patients with a previous intracranial hemorrhage. Overall, patients who received a contraindicated medication were less often obese, more often had chronic kidney disease, more often had a previous major bleeding event, and more often presented with an STEMI (Table 3) .
Unadjusted Association With Bleeding and Mortality Outcomes
Among patients with a known contraindication, the estimated cumulative incidence of periprocedural major bleeding was 22.7% (95% confidence interval [CI], 18.1-23.9) in patients who received a contraindicated medication and 9.4% (95% CI, 8.6-9.7) in patients who did not receive a contraindicated medication (P<0.001). The estimated incidence of 30-day mortality was 4.6% (95% CI, 3.0-6.0) among patients who received a contraindicated medication and 2.5% (95% CI, 2.2-2.8) among patients who did not receive a contraindicated medication (P=0.01). Of the 265 patients given abciximab, despite having ≥1 contraindication, there were no intracranial hemorrhages.
Association With Bleeding and Mortality Outcomes
As shown in the Figure, the 
Sensitivity Analysis
Our first-sensitivity analysis excluded 621 patients with STEMI that represented 97 of 737 (13.2%) patients using contraindicated medications. We observed similar relationships between contraindicated use of abciximab and eptifibatide with bleeding and mortality outcomes in this sensitivity analysis ( Figure II in the Data Supplement).
Our second-sensitivity analysis including periprocedrual anticoagulant use as a covariate did not meaningfully change the adjusted HRs for periprocedural major bleeding or 30-day mortality ( Figure III in the Data Supplement).
Our third-sensitivity analysis of using various truncation levels for the inverse probability weighting showed that most of our findings were robust to our chosen level of truncation. However, the estimated HR for bleeding among patients with a contraindication to abciximab because of a previous stroke was not significant using untruncated weights in the propensity score model, where the point estimate was 1.42 (95% CI, 0.97-2.10; Table III in the Data Supplement). It should be noted that increasing levels of truncation of the weights is accompanied with increasing bias, whereas reducing SEs of the effect estimates. Thus, our results about the effect of contraindicated abciximab on bleeding among previous stroke patients remain suggestive but not definitive.
Discussion
In this study of 64 294 patients undergoing PCI within the VA, the use of any contraindicated antiplatelet medications was associated with increased bleeding risk. Although the use of contraindicated medications was not significantly associated with risk-adjusted mortality, the point estimates suggested harm. Nearly 20% of patients undergoing PCI had a known contraindication to ≥1 antiplatelet medications, and >1 in 20 of those patients received a contraindicated medication. In adjusted analyses, use of abciximab in patients with contraindications of thrombocytopenia or previous stroke likely increased the risk of major bleeding.
Although the overall rate of contraindicated mediation use among patients with PCI is low (1.1%), this study highlights the problem of medication errors in the United States. Importantly, these data illustrate that the use of contraindicated antiplatelet medications persist, despite high-profile reports and EMR built-in warnings. 3 Medication errors are a major concern of the Joint Commission and represent a common element in their sentinel event database for establishing National Patient Safety Goals. 18 At times, there may be readily available safe alternatives that are not being used when indicated. Specifically, eptifibatide and tirofiban do not have absolute contraindications to use in patients with thrombocytopenia. These 2 agents have limited published efficacy and safety data in this population. [19] [20] [21] [22] Bivalirudin can be used without a Gp IIb/IIIa antagonist in patients with previous stroke. For antiplatelet therapy at discharge, clopidogrel or ticagrelor can be used in the place of prasugrel in patients with a previous stroke. Although certain bailout situations in STEMI care may CABG indicates coronary artery bypass surgery; COPD, chronic obstructive pulmonary disease; CVD, cerebrovascular disease; IQR, interquartile range; LMWH, lowmolecular-weight heparin; MI, myocardial infarction, NCDR, National Cardiovascular Data Registry; NSTEMI, non-ST-segment-elevation myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; PTSD, post-traumatic stress disorder; and STEMI, ST-segment-elevation myocardial infarction.
necessitate the consideration of contraindicated medication use, this potential situation explained only 13% of all contraindicated medication use without a difference in adjusted outcomes in the sensitivity analysis.
Our study expands on previous research of contraindicated medication use in the setting of PCI by assessing a larger number of medications, additional important contraindications, both periprocedural and discharge medications, and longer-term follow up. In 2009, Tsai et al 3 found that 22% of dialysis patients received a contraindicated periprocedural antithrombotic medication during PCI and that receipt of a contraindicated medication was associated with an increased risk of major bleeding. Although several of the medications used during PCI in contraindicated settings are used less frequently in contemporary practice (ie, GP IIb/ IIIa inhibitors), the importance of avoiding contraindicated medication use remains pertinent as newer therapies emerge. For example, Sherwood et al 23 identified the use of prasugrel in 3% of all PCI patients with a history of previous stroke. Hira et al 5 found that 13.9% of prasugrel patients in the PINNACLE national quality improvement registry had inappropriate (contraindicated) use, including use in previous stroke patients. They also noted significant site variability in the total proportion of prasugrel patients with inappropriate (contraindicated) use. Similarly, Sandhu et al 4 found contraindicated prasugrel use in 6% to 10% of patients in a Michigan statewide cardiac catheterization quality improvement collaborative. Pharmacy formulary restrictions at the VA may explain the lower rate of contraindicated prasugrel and ticagrelor use in our study. Given the risk of major bleeding, particularly with periprocedural medications, efforts to further reduce contraindicated antiplatelet medication use in this specialized setting are needed. Although studies have yet to demonstrate a statistically significant association between contraindicated medication use and mortality risk, the point estimates have suggested an association with increased mortality. 3 Our study is consistent with this previous study, but we cannot conclude a statistically significant association with mortality risk.
There are several possible explanations for the use of contraindicated antiplatelet medications in patients undergoing PCI. First, antiplatelet medications are often administered before they are entered into the medical chart in response to verbal orders given during the procedure, potentially limiting the ability for an EMR-triggered alert to prevent the use in patients with a known contraindication. Many procedures are performed urgently with limited opportunity to review patient data (with the patient or the EMR) at the time of critical medication decisions. Second, the volume of EMR warnings has been associated with medication alert fatigue and persistent adverse drug events. 24, 25 Some studies have suggested that the use of computerized physician order entry can reduce the use of contraindicated medications in hospitalized patients. 26 However, our study also suggests that an EMR and a computerized physician order entry are not sufficient to fully prevent periprocedural use of contraindicated medications because the VA includes the use of a robust EMR and computerized physician order entry system and the use of contraindicated medications still occurred. This may reflect the time-sensitive nature of these procedures and the need for verbal orders in this setting. However, even verbal orders could be checked by the members of the cath laboratory team using EMR-based alerts. In addition, not all known contraindications are currently flagged in the VA computerized physician order entry system, including contraindications based on time since diagnosis (eg, stroke). Future study to identify strategies that minimize the use of contraindicated medications may further improve the safety of procedures performed in the cardiac catheterization laboratory. Third, not all providers may be aware of the Food and Drug Administration package label contraindications or they may not agree with the label restrictions. Continued quality improvement efforts to educate providers about known contraindications may help to further reduce contraindicated medication use.
Strategies to reduce procedural use of contraindicated medications should consider a few specific factors. First, the role of patient-care team communication is essential to ensure awareness of concurrent medication use and comorbid medical conditions that might be known contraindications. Second, physician-nurse communication is a uniquely important opportunity to reduce contraindicated medication use in the cardiac catheterization laboratory given the frequency of verbal orders. Empowering nurses or other care team provides to identify potential medication contraindications and bring those to the physician's attention is integral to safe patient-care delivery. Third, educational efforts targeting physician and care-team knowledge about the potential medication contraindications should be included in any cardiac catheterization laboratory quality improvement activities. The effectiveness of each strategy for this specific clinical context remains to be studied.
Several important factors must be considered when interpreting this study. First, these results describe the practice pattern in VA catheterization laboratories and may not be generalizable to non-VA healthcare centers. However, previous studies suggest the use of contraindicated medications in the setting of PCI may be even more common in non-VA settings. 3, 23 Second, cath laboratory medication use is determined from provider documentation in the clinical record via the CART Program. The lack of additional pharmacy data on cath laboratory medication use may lead to an underestimation of contraindicated medication use. Third, our study was unable to identify if the use of contraindicated antiplatelet agents were associated with complex bail out situations. However, sensitivity analyses excluding patients with STEMI suggested only 13% of all contraindicated use occurred in this setting. Furthermore, exclusion of these patients did not negate the observed association between the contraindicated medication use and poor patient outcomes. Fourth, unmeasured confounders that could influence clinical outcomes associated with antiplatelet medication use must be considered. A wide range of clinical factors was used in the propensity-matched logistic regression model, thus minimizing this potential effect. Low body weight, which has been linked to bleeding risk in prasugrel patients, was not included in the NCDR bleeding risk score or our adjusted analyses. 12, 27 Medication dosing and concurrent use of anticoagulant medications, which could affect bleeding risk, were not assessed in this analysis. We were unable to assess for the upstream use of Gp IIb/IIIa inhibitors or other antiplatelet medications before a patient's arrival in the cardiac catheterization laboratory. Fifth, the sample size of patients with contraindicated medication use limited our ability to detect a statistically significant increased hazard for mortality (a type II or false-negative error). Sixth, we restricted our analysis to medications given in the periprocedural setting or hospital discharge to be consistent with previous studies. [3] [4] [5] 28 Evaluation of contraindicated medication use throughout the hospital stay is an area for future research. Seventh, medication allergies and adverse events were not assessed as potential reasons for contraindicated antiplatelet medication use. Eighth, although the HR and 95% CI for major bleeding in abciximab patient with thrombocytopenia was remarkably consistent across a range of inverse probability weighting truncation thresholds, the HR point estimate for major bleeding in abciximab patients with previous stroke declined with smaller truncation thresholds and the 95% CI crossed unity without any truncation. This might suggest that the potential of bias may be introduced when using these statistical methods to reduce variation between the cohorts. Finally, although administrative data used for ascertainment of some contraindications may not be as robust as other aspects of CART data that are captured in routine clinical care, the potential misclassification of contraindications would bias our findings toward the null. 8 In conclusion, in this national study of medication use in the setting of PCI, contraindicated medication use was relatively rare. Still, >1 in 20 patients with a contraindication to commonly used antiplatelet medications received a contraindicated medication with attendant bleeding risk. Further efforts to curb the use of contraindicated antiplatelet medications in the cardiac catheterization laboratory are needed.
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